ALBT (Avalon Globocare) LT-Debt-to-Total-Asset : 0.09 (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Avalon Globocare LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Avalon Globocare's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.09.

Avalon Globocare's long-term debt to total assets ratio declined from Sep. 2023 (0.22) to Sep. 2024 (0.09). It may suggest that Avalon Globocare is progressively becoming less dependent on debt to grow their business.

Avalon Globocare LT-Debt-to-Total-Asset Historical Data

The historical data trend for Avalon Globocare's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalon Globocare LT-Debt-to-Total-Asset Chart

Avalon Globocare Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.30

0.35

0.27

0.23

0.31

Avalon Globocare Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.22	0.31	0.32	0.33	0.09

Avalon Globocare LT-Debt-to-Total-Asset Calculation

Avalon Globocare's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	6.451	/	20.583
	=	0.31

Avalon Globocare's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	1.817	/	19.551
	=	0.09

Avalon Globocare (NAS:ALBT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Avalon Globocare LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Avalon Globocare's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalon Globocare Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Avalon Globocare Corp (NAS:ALBT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

4400 Route 9 South, Suite 3100, Freehold, NJ, USA, 07728

Website

https://www.avalon-globocare.com

Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

Executives

Lourdes Felix	director	15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
W J Tauzin	director	901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Wenzhao Lu	director, 10 percent owner	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Andrew Sanders	director	431 EAST 20TH STREET, NEW YORK NY 10010
Yancen Lu	director	14009 SE 50TH STREET, BELLEVUE WA 98006
Stilley William B. Iii	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Tevi Troy	director	611 SOMERSWORTH WAY, SILVER SPRING MD 20902
Luisa Ingargiola	officer: Chief Financial Officer	4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
David Jin	director, officer: CEO and President	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Yue Charles Li	director	C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9 SOUTH, SUITE 3100, FREEHOLD NJ 07728
Meng Li	director, officer: Chief Operating Officer	C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Philip Sukel	director	33 ALPINE DRIVE, MORGANVILLE NJ 07751